Page 18 - Read Online

Page 6 of 14 Daniele et al. Hepatoma Res 2021;7:61 https://dx.doi.org/10.20517/2394-5079.2021.58

Table 1. Characteristics of patients according to study arm
†
†
BSC (n = 16) BSC + Sorafenib
(n = 18)
Age
median (IQR) 65.6 (61.0; 70.5) 64.4 (53.5; 72.9)
< 70 63.2 (59.7; 67.0) 60.2 (49.8; 64.4)
70 75.4 (73.1; 77.6) 75.9 (72.9; 76.8)
Gender
Male 13 (81.3%) 16 (88.9%)
Female 3 (18.8%) 2 (11.1%)
Child-Pugh score
7 3 (18.8%) 6 (33.3%)
8 7 (43.8%) 7 (38.9%)
9 6 (37.5%) 5 (27.8%)
CLIP score
‡
1 1 (6.3%) 2 (11.1%)
2-3 11 (68.8%) 11 (61.1%)
4-5 4 (25.0%) 5 (27.8%)
ECOG performance status
§
0-1 11 (68.8%) 14 (77.8%)
2 5 (31.3%) 4 (22.2%)
Aetiology | 3 (18.8%) 3 (16.7%)
HBV infection 3 (18.8%) 3 (16.7%)
HBV DNA positive 1 (6.3%) 2 (11.1%)
HCV infection 12 (75.0%) 11 (61.1%)
HCV RNA positive 4 (25.0%) 2 (11.1%)
Alcohol 6 (37.5%) 8 (44.4%)
Esophageal varices
No 6 (37.5%) 7 (38.9%)
Present 8 (50.0%) 10 (55.6%)
Previous 2 (12.5%) 1 (5.6%)
Ascites
No 5 (31.3%) 6 (33.3%)
Mild 9 (56.3%) 12 (66.7%)
Moderate 2 (12.5%) 0 (0.0%)
Encephalopathy
Absent 15 (93.8%) 18 (100.0%)
Mild to moderate 1 (6.3%) 0 (0.0%)
Severe 0 (0.0%) 0 (0.0%)
Serum bilirubin
< 2.0 mg/dL 6 (37.5%) 7 (38.9%)
2-3 mg/dL 4 (25.0%) 7 (38.9%)
> 3.0 mg/dL 6 (37.5%) 4 (22.2%)
Serum albumin
> 3.5 g/dL 1 (6.3%) 1 (5.6%)
2.8-3.5 g/dL 10 (62.5%) 10 (55.6%)
< 2.8 g/dL 5 (31.3%) 7 (38.9%)
Prothrombin time
INR < 1.7 15 (93.8%) 17 (94.4%)